About the Trials
- Trial Name: Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE (EMERALD)
- ClinicalTrials.gov ID: NCT05001737
- Sponsor: Swedish Orphan Biovitrum
- Completion Date (Estimated): September 2025
- Trial Name: A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
- ClinicalTrials.gov ID: NCT03311854
- Sponsor: Swedish Orphan Biovitrum
- Completion Date: May 19, 2020
The sBLA acceptance and priority review come after positive data from 2 open-label, single-arm, interventional phase 3 studies—EMERALD (also called NI-0501-14; NCT05001737)3 and NI-0501-06 (NCT03311854)4—which enrolled a total of 39 patients with MAS. In these trials, patients received intravenous infusions of emapalumab, and in NI-0501-06, patients were given an initial dose of 6 mg/kg before continuing treatment with 3-mg/kg doses every 3 days until day 15, then twice per week for 2 weeks (until day 28).1,3,4
Key results—which were presented on November 19 at the 2024 American College of Rheumatology Convergence in Washington, DC—demonstrated that at week 8, approximately 53.8% (n = 21) of patients across both studies achieved a complete response (95% CI: 37.2%–69.9%) while receiving treatment with emapalumab. At any time during the studies’ durations, 33 patients (85%) achieved a complete response. Additionally, the weekly mean glucocorticoid doses were reduced by about 70.1% following 2 weeks of treatment, and by week 8, glucocorticoids were tapered to a clinically meaningful dose of 1 mg/kg/day or less in 28 patients (72%) and to 0.5 mg/kg/day or less in 17 patients (44%).2
Further, 32 patients (82.4%) achieved an overall response (OR) by week 8, and this was observed as early as day 5 (median time to first OR: 2.3 weeks). Clinical MAS remission was achieved by 32 patients (82.1%), with a median time to clinical remission of about 3.3 weeks. About 94.9% (n = 34) patients were alive at week 8. There were no new safety concerns identified in either of the studies.2
"HLH/MAS in Still disease is a serious and potentially fatal complication where patients can experience intense hyperinflammation and even multiple organ failure," Lydia Abad-Franch, MD, MBA, head of research and development, chief medical officer at Sobi, said in a news release. "There is no approved therapy for HLH/MAS today. Emapalumab selectively neutralizes IFN-γ, a key driver of hyperinflammation, and if approved, may also help reduce the need for high-dose glucocorticoids in these patients."1
REFERENCES
3. Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE (EMERALD). ClinicalTrials.gov identifier: NCT05001737. Updated October 15, 2024. Accessed February 27, 2025. https://clinicaltrials.gov/study/NCT05001737
4. A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH). ClinicalTrials.gov identifier: NCT03311854. Updated May 17, 2022. Accessed February 27, 2025. https://www.clinicaltrials.gov/study/NCT03311854